Phase 4
Completed N=63
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Source: ClinicalTrials.gov NCT03469271 ↗Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcomePrimary: Sniff Nasal Inspiratory Pressure (SNIP) — 90; 87; 89; 109 cmH20
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sniff Nasal Inspiratory Pressure (SNIP) |
90; 87; 89; 109 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of cancer
- Renal and hepatic function (creatinine </= 2 x the institutional upper limit of normal; bilirubin </= 2 x the institutional upper limit of normal)
- No contraindication to receive either of the planned interventions of inspiratory resistance training or 1,25(OH)2D3 in the opinion of the healthcare provider
- No difficulties with swallowing oral medications in the opinion of the enrolling physician
Exclusion Criteria
- Patient is taking calcium or Vitamin D supplements and is unwilling to stop for 8 weeks
- Severe chronic obstructive pulmonary disease (oxygen dependent or patient self-reports unable to walk one block without difficulty)
- Calcium or phosphorus level above the institutional upper limit of normal
Data sourced from ClinicalTrials.gov (NCT03469271). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.